SpyGlass Pharma, Inc. (SGP) Revenue, Earnings & Financial Statements
$31.44NASDAQ: SGPMarket Cap $1.05B
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
SpyGlass Pharma, Inc. most recently reported annual revenue of $0, a net loss of $40.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Income Statement — 1 Years (USD millions)
Metric
2025
Revenue
$0
Operating Expenses
$41.0M
Operating Profit
−$41.0M
Other Income
$2.0M
Interest
$0
Depreciation
$1.0M
Profit Before Tax
−$40.0M
Tax rate (%)
0.0%
Net Profit
−$40.0M
EPS
−$1.25
Quarterly Results — Last 5 Quarters (USD millions)
Metric
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
$0
Operating Expenses
$11.0M
$14.0M
$15.0M
$22.0M
$26.0M
Operating Profit
−$11.0M
−$14.0M
−$15.0M
−$22.0M
−$26.0M
Interest
$0
$0
$0
$0
$0
Profit Before Tax
−$10.0M
−$13.0M
−$14.0M
−$20.0M
−$24.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$10.0M
−$13.0M
−$14.0M
−$20.0M
−$24.0M
EPS
$0.00
−$0.38
−$0.69
−$0.59
−$0.73
Balance Sheet — 1 Years (USD millions)
Metric
2025
Total Assets
$116.0M
Current Assets
$109.0M
Cash
$96.0M
Inventory
$0
Receivables
$0
Fixed Assets
$4.0M
Capital Work in Progress
$0
Investments
$11.0M
Other Assets
$0
Total Liabilities
$215.0M
Current Liabilities
$9.0M
Borrowings
$2.0M
Other Liabilities
$213.0M
Equity
$0
Reserves
−$99.0M
For SpyGlass Pharma, Inc., free cash flow in the latest year was negative at $33.0M.
Cash Flow Statement — 2 Years (USD millions)
Metric
2024
2025
Operating Cash Flow
−$22.0M
−$33.0M
Investing Cash Flow
$22.0M
−$12.0M
Financing Cash Flow
$0
$125.0M
Net Cash Flow
$0
$80.0M
Free Cash Flow
−$24.0M
−$33.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.15
EV / EBITDA
-16.23
FCF Yield
-4.25%
Quick Ratio
25.06
Interest Coverage
—
Return 1Y
—
Return 3Y
—
Return 5Y
—
SpyGlass Pharma, Inc. (SGP) financials — frequently asked questions
What is SpyGlass Pharma, Inc.'s annual revenue?
SpyGlass Pharma, Inc. (SGP) reported annual revenue of $0 in its most recent fiscal year.
What is SpyGlass Pharma, Inc.'s net profit?
SpyGlass Pharma, Inc. (SGP) reported a net loss of $40.0M in its most recent fiscal year.
What is SGP EV/EBITDA?
SpyGlass Pharma, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -16.23. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks